...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Platelets >Evaluation of platelet function in thrombocytopenia
【24h】

Evaluation of platelet function in thrombocytopenia

机译：血小板减少症血小板功能的评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Whole blood aggregometry is a functional assay for determination of platelet function. Until now, whole blood aggregometry has not been considered feasible at low platelet counts. Hence, the objectives of the present study were to explore platelet function in thrombocytopenia using a novel index of impedance aggregometry adjusted for platelet count and evaluate the association to platelet function assessed by flow cytometry. Hirudin anticoagulated blood was collected from 20 healthy volunteers, 20 patients with primary immune thrombocytopenia (ITP), and 17 hematological cancer patients. Platelet function was analyzed by impedance aggregometry and by flow cytometry. Collagen, adenosine diphosphate, thrombin receptor agonist peptide-6, and ristocetin were used as agonists for both analyses. Thrombocytopenia in healthy whole blood was induced in vitro employing a recently published method. Platelet aggregation of thrombocytopenic patients was evaluated relative to the aggregation of healthy volunteers at the same platelet count. In flow cytometry, platelet function was described as expression of the platelet surface glycoproteins: bound fibrinogen, CD63, and P-selectin. Similar platelet counts were obtained in the patient groups (p = 0.69) (range: 13-129 x 10(9)/l). Aggregation adjusted for platelet count was significantly increased in ITP patients compared to healthy platelets across all agonists. The platelet aggregation was high in the 95% prediction interval, with 18 ITP patients above the prediction interval in at least two agonists. In contrast, the platelet aggregation was low in the prediction interval in cancer patients, and three cancer patients with platelet aggregation below the prediction interval in at least one agonist. ITP patients displayed increased expression of bound fibrinogen and CD63 following activation, compared with particularly cancer patients, but also compared with healthy platelets. This study demonstrated the feasibility of a novel approach to perform platelet function analyses in thrombocytopenia using impedance aggregometry adjusted for platelet count.
机译：全血聚测定法是用于测定血小板功能的功能测定。到目前为止，整个血液聚集体在低血小板计数下尚未被认为是可行的。因此，本研究的目的是利用对血小板计数调节的抗冲击性的新颖指数来探讨血小板减少症的血小板功能，并评估通过流式细胞术评估的血小板函数的关联。从20名健康志愿者收集了血列抗凝血液，20名患有患有17名血液癌症患者的20名健康志愿者。通过阻抗聚合物和流式细胞术分析血小板函数。胶原蛋白，腺苷二磷酸，凝血酶受体激动剂肽-6和ristocetin被用作两种分析的激动剂。血小板减少在健康的全血中诱导在体外采用最近发表的方法。相对于相同血小板计数的健康志愿者的聚集评估血小板减薄患者的血小板聚集。在流式细胞术中，血小板功能被描述为血小板表面糖蛋白的表达：结合的纤维蛋白原，CD63和P-SELETIN。在患者基团中获得类似的血小板计数（P = 0.69）（范围：13-129×10（9）/ L）。与血小板计数调整的聚集在ITP患者中，与所有激动剂的健康血小板相比显着增加。血小板聚集在95％预测间隔中高，预测间隔高于至少两个激动剂的18个ITP患者。相反，血小板聚集在癌症患者的预测间隔中低，并且三个癌症患者在至少一种激动剂中预测间隔低于预测间隔。 ITP患者在激活后显示出纤维蛋白原和CD63的结合纤维蛋白原和CD63的表达增加，与尤其是癌症患者相比，但也与健康血小板相比。本研究表明，使用对血小板计数调节的阻抗聚体进行血小板衰竭在血小板病变中进行血小板功能分析的新方法的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号